Blood disease

| CRISPR Medicine | This is an overview of articles related to blood disorders

First cancer patient dosed in CRISPR-armed phage...

Jun. 12, 2025

SNIPR Biome has dosed the first patient in its Phase 1b trial of SNIPR001, a CRISPR-CAS-armed bacteriophage therapy that represents a new frontier in...

Startup Spotlight: Ariya Bio - A Unique...

Nov. 6, 2023

Located in the ETH Innovation & Entrepreneurship Lab in Zürich (Switzerland), Ariya Bio's goal is to develop safe and effective gene-editing therapies...

Disease Roundup: Four Gene-Editing Candidates in...

Sep. 20, 2023

There are currently four clinical-stage gene-editing candidates in clinical trials for sickle cell disease, which affects millions of people worldwide...

CRISPR Trial Update: Editas Reports Positive...

Jun. 14, 2023

Editas Medicine recently announced positive initial safety and efficacy data for its CRISPR-edited cell therapy EDIT-301. The data was obtained from...

Clinical Trial Update: Recent News From Editas...

May. 3, 2023

In this clinical update, we look at recent advances in two clinical-stage gene-editing programmes. Editas Medicine's sickle cell disease candidate...

CRISPR IND Updates: E. coli, Beta Thalassemia, and...

Jan. 12, 2022

In our first clinical update of 2022, we look at three new IND approvals for gene-edited therapies for life-threatening E. coli infections,...

CRISPR Medicine in 2021 – What a Phenomenal Year...

Dec. 28, 2021

In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...

CMN Weekly (10 December 2021) - Your Weekly CRISPR...

Dec. 10, 2021

Some of the best links we picked up around the internet